6 June 2021 • 4 minute read
DLA Piper advises Trajan Scientific and Medical on its IPO and ASX Listing
Global law firm DLA Piper is proud to have advised Trajan Scientific and Medical (Trajan) on its successful initial public offering (IPO) and ASX listing.
Trajan is a Melbourne based global developer and manufacturer of analytical and life sciences instruments and devices which was established by Stephen and Angela Tomisich in 2011.
Trajan’s shares commenced trading on the ASX today – Monday, 7 June 2021.
The IPO raised $90 million at an offer price of $1.70 per share. The proceeds raised under the IPO are intend to be used by Trajan to execute on its exciting global growth initiatives.
The IPO was a complex transaction which involved preparing a substantial global business for admission to the Australian Securities Exchange (ASX).
The cross-jurisdictional team was led by partner Chris Mitchell with support from senior associate Chanel Mercurio, and solicitors Simon Rimmelzwaan and Davina Khoo. Chris and the Australian team were supported by colleagues from the United States, United Kingdom, Japan, Singapore, Canada, France, Switzerland, Germany and Denmark.
Chris Mitchell commented “It was an absolutely pleasure to assist Trajan on their ASX listing. A big congratulations to founders, Stephen and Angela Tomisich, who have created an incredible company with global infrastructure, unique technologies and, importantly, a dedicated team that is truly focused on science that benefits people and having an impact on human wellbeing. We look forward to continuing to support the Trajan team as they implement their global growth initiatives.”
Trajan’s CEO and co-founder Stephen Tomisich commented “DLA Piper played a critical role in our successful IPO, they lead the program with discipline and intensity ensuring on time delivery of the vital milestones along the way.” “The IPO process went very smoothly which was testament to the collaborative approach and hard work from everyone involved.” added Stephen.
The transaction leveraged DLA Piper’s extensive global platform and is another example of DLA Piper’s market-leading position as M&A and equity capital market advisors to fast growth companies.
Trajan is a Melbourne based global developer and manufacturer of analytical and life sciences instruments and devices which was established by Stephen and Angela Tomisich in 2011.
Trajan’s shares commenced trading on the ASX today – Monday, 7 June 2021.
The IPO raised $90 million at an offer price of $1.70 per share. The proceeds raised under the IPO are intend to be used by Trajan to execute on its exciting global growth initiatives.
The IPO was a complex transaction which involved preparing a substantial global business for admission to the Australian Securities Exchange (ASX).
The cross-jurisdictional team was led by partner Chris Mitchell with support from senior associate Chanel Mercurio, and solicitors Simon Rimmelzwaan and Davina Khoo. Chris and the Australian team were supported by colleagues from the United States, United Kingdom, Japan, Singapore, Canada, France, Switzerland, Germany and Denmark.
Chris Mitchell commented “It was an absolutely pleasure to assist Trajan on their ASX listing. A big congratulations to founders, Stephen and Angela Tomisich, who have created an incredible company with global infrastructure, unique technologies and, importantly, a dedicated team that is truly focused on science that benefits people and having an impact on human wellbeing. We look forward to continuing to support the Trajan team as they implement their global growth initiatives.”
Trajan’s CEO and co-founder Stephen Tomisich commented “DLA Piper played a critical role in our successful IPO, they lead the program with discipline and intensity ensuring on time delivery of the vital milestones along the way.” “The IPO process went very smoothly which was testament to the collaborative approach and hard work from everyone involved.” added Stephen.
The transaction leveraged DLA Piper’s extensive global platform and is another example of DLA Piper’s market-leading position as M&A and equity capital market advisors to fast growth companies.